Abstract: A pharmaceutical composition for enhancing male erectile function comprising an erectile function-enhancing amount of an insulin-like growth factor selected from the group consisting of IGF-1 (Somatmedin-C) and analog LR3 IGF1 in admixture with a pharmaceutically-acceptable diluents or carrier. Such compositions optionally further comprise compounds selected from an androgen, particularly, testosterone and dihydrotestosterone, a vasodilator, PDE5 inhibitor and prostaglandin E1.

Abstract: According to an aspect, a medical device includes a needle member having a curved portion, a handle coupled to the needle member, and a pusher member including a sheath and an extension member. The sheath may be bendable. The extension member is configured to be slidably coupled to a track of the handle such that extension member slides within the track during a medical procedure. The sheath defines a lumen configured to receive a portion of the needle member. The extension member is configured to be de-coupled from the track of the handle after the medical procedure. The sheath is configured to be de-coupled from the needle member after the medical procedure. In some examples, the sheath of the pusher member is configured to bend to conform to the curved portion when the sheath of the pusher member is moved over the curved portion of the needle member.

Abstract: According to an aspect, a medical device may include a needle member, and a handle coupled to the needle member. The handle may define a track portion. The medical device may also include a pusher member having a sheath disposed around a portion of the needle member, and an extension member being movably coupled to the track portion of the handle such that the pusher member is configured to move from a first position to a second position during a surgical procedure. The pusher member may be removable from the handle. The sheath may define a slot, and the pusher member may be removable from the needle member through the slot.

Abstract: Some embodiments are directed to implants and methods for making and using the implants. An exemplary implant includes a first elongate member and a second elongate member each having a first end portion and a second end portion. The first and second end portions of the first elongate member may be configured to be coupled to tissue of a patient proximate the vagina and sacrum, respectively. The first elongate member may define a first opening and a second opening, where the second elongate member may be configured to extend through the first opening and the second opening. The first end portion of the second elongate member may be coupled to tissue proximate the vagina of the patient.

Abstract: A medical device includes an elongate member. The elongate member has a first end portion and a second end portion. The second end portion of the elongate member has an upper surface and a lower surface disposed opposite the upper surface. The lower surface has a planar portion. The upper surface has a planar portion and a concave portion.

Abstract: A composition, use of and a method of removing a hyperplastic skin lesion on a mammal comprising administering to the lesion or locus thereof a therapeutically effective amount of a composition comprising a blocker selected from the group consisting of a calcium channel blocker, a metabolite thereof, a calmodulin blocker and a metabolite thereof and a pharmaceutically acceptable diluent or carrier.

Abstract: The use of an aromatase blocker or an estrogen blocker is described in a method for increasing spermatogenesis and Seritolli cell function, and/or improving Leydig cell function, in order to to increase endogenous testosterone levels in a male mammal. The levels of active materials used are significantly lower than the levels of these materials used to treat female estrogen sensitive tumors.

Abstract: A method and device to deliver medication in a liquid, gel or suspension formulation to a plurality of adjacent tissue sites of a mammal, the device comprising a plurality of tissue-engaging members for receiving the medication and operably engageable with the plurality of tissue sites; means for supplying the tissue-engaging members with the formulation, and to temporarily sustain and control the rate of therapeutic agent/unit of time and preferably to sustain these controlled delivery rates over extended periods of time to enhance the local therapeutic effect of these therapeutic agents and to reduce the systemic toxicity and reduce unwanted side effects.

Abstract: In the broadest aspect, the invention provides a composition for and a method of prophylactic and/or therapeutic treatment of a animal/mammal for any viral disease, mixed bacterial and viral infections, bacterial infections, bacterial endotoxins, bacterial exotoxins, autoimmune diseases, and cellular or humoral mediated allergic conditions that is caused by any virus that relies on the maintenance of specific calcium ion concentrations for the post ribosomal RNA synthesis processing of viral protein translation, transportation and processing of viral structural components by utilizing a therapeutic amount of a blocker selected from the group consisting of a calcium channel blocker, a metabolite thereof, a calmodulin blocker and a metabolite thereof, and a pharmaceutical acceptable diluent or carrier; and/or is caused by damage to the animal/mammal by a pathological immune response to antigens.

Abstract: Pharmaceutical compositions and methods for improving functional capacity of tissues and organs in both healthy and pathologic disease states for: reducing unwanted cosmetic effects of aging on the skin to reduce wrinkles, to increase collagen and water content, thicken and increase skin volume and to maintain a youthful appearance to age and sun damaged skin, to treat diseases of skin and tissues caused by ischemia of venous congestion and arterial insufficiency, to accelerate healing of tendons, ligaments, joints, cartilage, nerves, bones or neuromuscular injuries or diseases, to improve and restore the functional capacity of specific tissues and organs of the body, and to treat hair loss comprising an effective amount of an insulin-like growth factor selected from the group consisting of IGF-1 (Somatmedin-C) and analogue LR3 IGF1 in admixture with a pharmaceutically-acceptable diluent or carrier.

Abstract: A penis tensioning device effecting penis tissue modeling and penis enlargement, the device comprising an elongate tensioning, biasing member having a first portion (14) and a second portion; first retaining means connected to the first portion (14) and Cooperable in tight-fitting engagement with a portion of the penis adjacent the head; second retaining means connected to the second portion and cooperable with a distal member selected from the group consisting of an article of clothing, a body part and an inanimate object.

Abstract: A composition, use of and a method of removing a hyperplastic skin lesion on a mammal comprising administering to the lesion or locus thereof a therapeutically effective amount of a composition comprising a blocker selected from the group consisting of a calcium channel blocker, a metabolite thereof, a calmodulin blocker and a metabolite thereof and a pharmaceutically acceptable diluent or carrier.

Abstract: A pharmaceutical composition for enhancing male erectile function comprising an erectile function-enhancing amount of an insulin-like growth factor selected from the group consisting of IGF-1 (Somatmedin-C) and analogue LR3 IGF1 in admixture with a pharmaceutically-acceptable diluents or carrier. Such compositions optionally further comprise compounds selected from an androgen, particularly, testosterone and dihydrotestosterone, a vasodilator, PDE5 inhibitor and prostaglandin E1.

Abstract: A method for causing a permanent increase in the length and girth of a male subject's penis, the method comprising treatment comprising the step of (a) administering to the male an effective amount of a vasodilator selected from the group consisting of a vasodilator per se and compositions thereof comprising a pharmaceutically-acceptable diluent or carrier, to induce a cumulative prolonged engorgement of the subject's penis; and (b) repeating step (a) as necessary to cause the increase during the treatment. A potentiator which enhances the effect of the vasodilator may also be used.

Abstract: A method for causing a permanent increase in the length and girth of a male subject's penis, the method comprising treatment comprising the step of (a) administering to the male an effective amount of a vasodilator selected from the group consisting of a vasodilator per se and compositions thereof comprising a pharmaceutically-acceptable diluent or carrier, to induce a cumulative prolonged engorgement of the subject's penis; and (b) repeating step (a) as necessary to cause the increase during the treatment. A potentiator which enhances the effect of the vasodilator may also be used.

Abstract: A penis tensioning device effecting penis tissue modeling and penis enlargement, the device comprising an elongate tensioning, biasing member having a first portion (14) and a second portion; first retaining means connected to the first portion (14) and cooperable in tight-fitting engagement with a portion of the penis adjacent the head; second retaining means connected to the second portion and cooperable with a distal member selected from the group consisting of an article of clothing, a body part and an inanimate object.